» Articles » PMID: 37430070

Implications of Immunometabolism for Smouldering MS Pathology and Therapy

Overview
Journal Nat Rev Neurol
Specialty Neurology
Date 2023 Jul 10
PMID 37430070
Authors
Affiliations
Soon will be listed here.
Abstract

Clinical symptom worsening in patients with multiple sclerosis (MS) is driven by inflammation compartmentalized within the CNS, which results in chronic neuronal damage owing to insufficient repair mechanisms. The term 'smouldering inflammation' summarizes the biological aspects underlying this chronic, non-relapsing and immune-mediated mechanism of disease progression. Smouldering inflammation is likely to be shaped and sustained by local factors in the CNS that account for the persistence of this inflammatory response and explain why current treatments for MS do not sufficiently target this process. Local factors that affect the metabolic properties of glial cells and neurons include cytokines, pH value, lactate levels and nutrient availability. This Review summarizes current knowledge of the local inflammatory microenvironment in smouldering inflammation and how it interacts with the metabolism of tissue-resident immune cells, thereby promoting inflammatory niches within the CNS. The discussion highlights environmental and lifestyle factors that are increasingly recognized as capable of altering immune cell metabolism and potentially responsible for smouldering pathology in the CNS. Currently approved MS therapies that target metabolic pathways are also discussed, along with their potential for preventing the processes that contribute to smouldering inflammation and thereby to progressive neurodegenerative damage in MS.

Citing Articles

Coenzyme A fueling with pantethine limits autoreactive T cell pathogenicity in experimental neuroinflammation.

Angiari S, Carlucci T, Budui S, Bach S, Dusi S, Walter J J Neuroinflammation. 2024; 21(1):287.

PMID: 39501296 PMC: 11536535. DOI: 10.1186/s12974-024-03270-w.

References
1.
Reich D, Lucchinetti C, Calabresi P . Multiple Sclerosis. N Engl J Med. 2018; 378(2):169-180. PMC: 6942519. DOI: 10.1056/NEJMra1401483. View

2.
Larochelle C, Uphaus T, Prat A, Zipp F . Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?. Trends Neurosci. 2016; 39(5):325-339. DOI: 10.1016/j.tins.2016.02.001. View

3.
Tintore M, Vidal-Jordana A, Sastre-Garriga J . Treatment of multiple sclerosis - success from bench to bedside. Nat Rev Neurol. 2018; 15(1):53-58. DOI: 10.1038/s41582-018-0082-z. View

4.
Bittner S, Zipp F . Progression in multiple sclerosis - a long-term problem. Curr Opin Neurol. 2022; 35(3):293-298. DOI: 10.1097/WCO.0000000000001044. View

5.
Frischer J, Weigand S, Guo Y, Kale N, Parisi J, Pirko I . Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015; 78(5):710-21. PMC: 4623970. DOI: 10.1002/ana.24497. View